Replimune's IGNYTE Trial Analysis Chosen for Oral Presentation at ESMO Congress 2024

Replimune Group, Inc., a biotechnology firm specializing in oncolytic immunotherapies, announced that a late-breaking abstract from their IGNYTE clinical trial will be featured in an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2024. The event is scheduled for September 13-17, 2024, in Barcelona.

The abstract will present primary efficacy, safety, and survival data from a cohort of patients with anti-PD-1-failed melanoma treated with RP1 combined with nivolumab. This presentation is set for September 15, 2024, from 3:45 to 3:50 p.m. CEST and will be delivered by Dr. Caroline Robert of the Gustave Roussy Cancer Center during the Mini Oral Session on Melanoma and other skin tumors.

RP1, also known as vusolimogene oderparepvec, is Replimune’s leading product candidate. It is developed from a unique strain of the herpes simplex virus, which has been genetically modified to include a fusogenic protein (GALV-GP R-) and GM-CSF. This combination aims to enhance the virus's ability to kill tumor cells, increase the immunogenicity of tumor cell death, and stimulate a systemic anti-tumor immune response.

Replimune, established in 2015 and based in Woburn, MA, is dedicated to revolutionizing cancer treatment through its pioneering oncolytic immunotherapy portfolio. The company’s RPx platform is designed on a robust HSV-1 backbone to promote immunogenic cell death and trigger a systemic anti-tumor immune response. The platform exhibits dual local and systemic activity by selectively targeting and destroying tumor cells, releasing tumor-derived antigens, and modifying the tumor environment to provoke a robust and durable immune response.

The RPx product candidates are expected to work synergistically with most existing and experimental cancer treatments, allowing for development either as standalone therapies or in combination with other options. This flexibility enhances the versatility and potential efficacy of the RPx platform in various therapeutic settings.